Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.

Ghadjar, Pirus; Aebersold, Daniel; Albrecht, Clemens; Böhmer, Dirk; Flentje, Michael; Ganswindt, Ute; Höcht, Stefan; Hölscher, Tobias; Müller, Arndt-Christian; Niehoff, Peter; Pinkawa, Michael; Sedlmayer, Felix; Zips, Daniel; Wiegel, Thomas (2020). Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer. Strahlentherapie und Onkologie, 196(7), pp. 589-597. Springer 10.1007/s00066-020-01598-9

[img]
Preview
Text
Ghadjar2020_Article_TreatmentStrategiesToPreventAn.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (275kB) | Preview

AIM To provide an overview on the available treatments to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. METHODS The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published and assessed the validity of the information on efficacy and treatment-related toxicity. RESULTS Eight randomized controlled trials and one meta-analysis were identified. Two randomized trials demonstrated that prophylactic radiation therapy (RT) using 1 × 10 Gy or 2 × 6 Gy significantly reduced the rate of gynecomastia but not breast pain, as compared to observation. A randomized dose-finding trial identified the daily dose of 20 mg tamoxifen (TMX) as the most effective prophylactic dose and another randomized trial described that daily TMX use was superior to weekly use. Another randomized trial showed that prophylactic daily TMX is more effective than TMX given at the onset of gynecomastia. Two other randomized trials described that TMX was clearly superior to anastrozole in reducing the risk for gynecomastia and/or breast pain. One comparative randomized trial between prophylactic RT using 1 × 12 Gy and TMX concluded that prophylactic TMX is more effective compared to prophylactic RT and furthermore that TMX appears to be more effective to treat gynecomastia and/or breast pain when symptoms are already present. A meta-analysis confirmed that both prophylactic RT and TMX can reduce the risk of gynecomastia and/or breast pain with TMX being more effective; however, the rate of side effects after TMX including dizziness and hot flushes might be higher than after RT and must be taken into account. Less is known regarding the comparative effectiveness of different radiation fractionation schedules and more modern RT techniques. CONCLUSIONS Prophylactic RT as well as daily TMX can significantly reduce the incidence of gynecomastia and/or breast pain. TMX appears to be an effective alternative to RT also as a therapeutic treatment in the presence of gynecomastia but its side effects and off-label use must be considered.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Aebersold, Daniel

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1439-099X

Publisher:

Springer

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

21 Apr 2020 11:29

Last Modified:

22 Jun 2020 01:32

Publisher DOI:

10.1007/s00066-020-01598-9

PubMed ID:

32166452

Uncontrolled Keywords:

Antiandrogen therapy Breast pain Gynecomastia Prostate cancer Treatment

BORIS DOI:

10.7892/boris.142435

URI:

https://boris.unibe.ch/id/eprint/142435

Actions (login required)

Edit item Edit item
Provide Feedback